GNPX

Genprex Inc

1.98

Oct 22 • 3:58 PM ET -0.07 (-3.41%)

2.01

Aftermarket • 5:47 PM ET +0.03 (1.32%)

Healthcare Biotechnology USA Nano NASD

Peers: IMNN CLDI INO TOVX GNLX CADL GOVX ONCY PDSB MTVA

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	1.62M
Enterprise Value	-13.53M
Income	-16.50M
Sales	0.00M
Book/sh	29.23
Cash/sh	18.49
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	Mar 29, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.07
P/C	0.11
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.77
Current Ratio	6.77
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-158.75
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	74.00% 55.62%
Sales past 3/5Y	- -
EPS Y/Y TTM	93.08%
Sales Y/Y TTM	-
EPS Q/Q	94.96%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	0.00% -

Insider Own	0.21%
Insider Trans	0.00%
Inst Own	1.66%
Inst Trans	1.22%
ROA	-157.40%
ROE	-203.86%
ROIC	-111.51%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-21.79%
SMA50	-38.94%
SMA200	-90.96%
Trades

Shs Outstand	0.82M
Shs Float	0.82M
Short Float	11.84%
Short Ratio	0.36
Short Interest	0.10M
52W High	249.48 -99.21%
52W Low	1.91 3.66%
Volatility	10.06% 10.89%
ATR (14)	0.25
RSI (14)	24.19
Beta	-0.98
Rel Volume	0.34
Avg Volume	269.21K
Volume	91,577

Perf Week	-13.54%
Perf Month	-47.20%
Perf Quarter	-74.65%
Perf Half Y	-91.18%
Perf YTD	-94.86%
Perf Year	-99.18%
Perf 3Y	-99.98%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	1.00
Target Price	8250.00
Prev Close	2.05
Price	1.98
Change %	-3.41%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-21	Initiated	National Securities	Buy	$7
Apr-29-19	Initiated	Noble Capital Markets	Outperform	$5

Oct-21-26 07:00AM	Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA, in Maintaining Cellular Function During Brain Aging (PR Newswire)
Sep-08-26 08:00AM	Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-18-26 07:00AM	Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy (PR Newswire) -11.73%
Aug-03-26 08:46AM	Genprex Shares Rise After Collaboration With Roche Diagnostics (InvestorsHub) -20.70%
07:00AM	Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies (PR Newswire)
06:36AM	Loading…
Jun-23-26 06:36AM	Genprex's Reqorsa combo secures Canadian patent for lung cancer (Pharmaceutical Business Review) -5.29%
Jun-22-26 09:00AM	Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer (PR Newswire) -7.08%
Jun-17-26 09:00AM	Genprex to Participate at BIO International Convention 2026 (PR Newswire) +10.95%
May-26-26 08:00AM	Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy Published at the 2026 ASCO Annual Meeting (PR Newswire) -5.98%
May-14-26 08:00AM	Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting (PR Newswire)
Apr-30-26 08:00AM	Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer (PR Newswire) +12.07%
Apr-28-26 07:00AM	Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting (PR Newswire)
Apr-22-26 07:00AM	Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting (PR Newswire) -6.42%
Apr-21-26 07:00AM	Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy (PR Newswire) -5.63%
Apr-20-26 07:00AM	Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting (PR Newswire) -11.15%
07:00AM	Loading…
Mar-18-26 07:00AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting (PR Newswire)
Mar-10-26 07:00AM	Genprex to Participate at BIO Europe Spring 2026 (PR Newswire)
Feb-25-26 06:20PM	Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying (Benzinga) -9.46% +5.97%
Feb-23-26 08:00AM	Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer (PR Newswire) +27.53%
Feb-10-26 08:00AM	Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers (PR Newswire)
Jan-09-26 11:30AM	Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of (Benzinga) +10.00%
Jan-07-26 07:00AM	Genprex Provides Clinical Update on Diabetes Gene Therapy Program (PR Newswire)
Jan-06-26 07:00AM	Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies (PR Newswire) +5.00%
Nov-24-25 07:00AM	Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer (PR Newswire) -6.67%
Nov-19-25 07:03AM	USPTO grants patent to Genprex's Reqorsa gene therapy (Pharmaceutical Business Review) -9.49%
07:00AM	Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials (PR Newswire)
Nov-18-25 07:00AM	Genprex Announces U.S. Patent for Reqorsa Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers (PR Newswire) -8.66%
Nov-04-25 07:00AM	Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer (PR Newswire) -11.32%
Oct-28-25 11:19AM	Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -20.11%
07:00AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
08:12AM	Loading…
Oct-23-25 08:12AM	Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules (PR Newswire) -16.42%
Oct-14-25 07:00AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) +30.15%
Sep-05-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +47.40%
Sep-02-25 08:30AM	Genprex to Present and Participate at Upcoming September Investor and Industry Conferences (PR Newswire)
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-22-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +17.04%
Aug-18-25 09:29AM	Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers (PR Newswire) -10.04%
Aug-04-25 08:30AM	Genprex Issues Stockholder Letter and Provides 2025 Corporate Update (PR Newswire) +6.06%
Jun-24-25 09:25AM	Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions (PR Newswire) +9.17%
Jun-23-25 09:00AM	Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions (PR Newswire) -13.22%
Jun-03-25 07:00AM	Genprex to Participate at BIO 2025 International Convention (PR Newswire) -10.16%
May-29-25 07:00AM	Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting (PR Newswire) +18.89%
May-28-25 07:00AM	Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting (PR Newswire)
May-07-25 07:00AM	Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes (PR Newswire)
May-06-25 07:00AM	Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma (PR Newswire) -5.68%
Apr-30-25 07:30AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting (PR Newswire)
Apr-29-25 07:30AM	Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting (PR Newswire)
Apr-28-25 07:30AM	Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma (PR Newswire)
Apr-24-25 08:15AM	Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting (PR Newswire) +14.62%
Apr-22-25 08:15AM	Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings (PR Newswire)
Mar-26-25 08:15AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting (PR Newswire)
Mar-25-25 08:15AM	Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions (PR Newswire)
Mar-04-25 08:15AM	Genprex to Participate at BIO Europe Spring 2025 (PR Newswire)
Feb-19-25 08:15AM	Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System (PR Newswire)
Feb-18-25 08:15AM	Genprex Provides Update on Diabetes Gene Therapy Program (PR Newswire) -7.01%
Feb-13-25 08:15AM	Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer (PR Newswire)
Jan-24-25 07:28AM	Genprex doses first subject in expansion part of lung cancer gene therapy trial (Clinical Trials Arena)
Jan-23-25 08:00AM	Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa Gene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) -6.25%
Jan-14-25 09:28AM	Genprex Advances Cancer Trials and Diabetes Therapy (TipRanks)
Jan-06-25 09:15AM	Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-16-24 09:15AM	Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer (PR Newswire) -9.48%
Nov-21-24 10:16AM	Genprex links with University of Michigan on lung cancer treatment (Pharmaceutical Technology)
Nov-20-24 09:29AM	Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer (PR Newswire) -14.40%
Nov-05-24 09:29AM	Genprex Collaborators Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting (PR Newswire) -10.40%
Oct-31-24 09:29AM	Genprex to Participate in 2024 BIO Europe Conference (PR Newswire) +11.39%
Oct-28-24 09:29AM	Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma (PR Newswire) +38.38%
Oct-24-24 09:29AM	Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive (PR Newswire) -19.25%
Oct-16-24 07:45AM	Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa (Clinical Trials Arena)
Oct-15-24 09:29AM	Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer (PR Newswire)
Oct-10-24 09:29AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire)
Oct-07-24 09:29AM	Genprex Collaborators to Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting (PR Newswire)
Sep-23-24 09:29AM	Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes (PR Newswire) +8.85%
Sep-19-24 09:29AM	Genprex Announces Formation of Mesothelioma Clinical Advisory Board (PR Newswire) +6.85%
Sep-09-24 09:29AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-04-24 09:29AM	Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes (PR Newswire) -19.70%
Sep-03-24 08:15AM	Genprex to Present and Participate at Upcoming September Investor and Industry Conferences (PR Newswire)
Aug-15-24 09:30AM	Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials (PR Newswire) -10.72%
Aug-14-24 09:25AM	Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer (PR Newswire) -14.11%
Aug-13-24 08:31AM	Genprex Granted Patent in Singapore for Reqorsa Gene Therapy with PD-1 Antibodies to Treat Cancers (PR Newswire) -32.52%
Aug-08-24 08:30AM	Genprex to Present at the August Sidoti Microcap Conference (PR Newswire)
Jun-27-24 08:31AM	Genprex Issues Stockholder Letter and Provides 2024 Corporate Update (PR Newswire)
May-30-24 08:31AM	Genprex to Present at the 2024 BIO International Convention (PR Newswire)
May-20-24 12:53PM	GNPX Stock Earnings: Genprex Beats EPS for Q1 2024 (InvestorPlace)
May-15-24 04:42AM	Genprex dosing subjects in trial of combination therapy for small-cell lung cancer (Clinical Trials Arena)
May-14-24 08:31AM	Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +7.53%
May-13-24 08:31AM	Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors (PR Newswire)
May-08-24 06:08PM	Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner (PR Newswire) -6.05%
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) -5.13%
May-01-24 08:31AM	Genprex to Present and Participate at Upcoming May Investor and Industry Conferences (PR Newswire)
Apr-09-24 08:31AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 08:57AM	Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up (Zacks)
Apr-03-24 08:31AM	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +9.51%
Apr-02-24 08:31AM	Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System (PR Newswire)
Mar-22-24 04:10PM	Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Mar-19-24 01:24PM	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.36%
Mar-12-24 09:01AM	Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers (PR Newswire) -10.43%
Mar-06-24 08:30AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire) +6.31%
Feb-07-24 08:15AM	Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators (PR Newswire) -11.17%
Feb-06-24 07:30AM	Genprex to Present at Upcoming BIO CEO & Investor Conference (PR Newswire) -10.45%
Feb-05-24 07:30AM	Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer (PR Newswire) +13.37%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LONGNECKER BRENT M	Director	Apr 14 '26	Sale	1.23	10	12	0	Apr 15 06:50 PM
LONGNECKER BRENT M	Director	Apr 14 '26	Sale	1.23	8	10	9,157	Apr 15 06:50 PM

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

PresidentMr. Ryan M. Confer M.S.

Chief Medical OfficerDr. Mark S. Berger M.D.

Senior Vice President of Human ResourcesMr. David M. Schloss

Senior Vice President of Intellectual Property & LicensingMr. Thomas C. Gallagher Esq.

Senior Vice President of Regulatory Affairs & QualityDr. Suzanne Thornton-Jones Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNPX

Genprex Inc

Upgrade your Finviz experience